机构：[1]Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.临床科室河北省肿瘤研究所河北医科大学第四医院[2]College of Public Health, Hebei Medical University, Shijiazhuang 050031, China.[3]Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang 050000, China.[4]Candidate Branch of National Clinical Research Center for Skin Diseases, Shijiazhuang 050000, China.[5]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.临床科室胸心外科（胸外科 心脏血管外科）河北医科大学第四医院
We aimed to explore the effect of CD39 expression on CD8+ T cells and on the diagnosis and prognosis of esophageal squamous cell carcinoma (ESCC). The independent prognostic factors for the surgical specimens of the 95 ESCC patients were screened by multivariate Cox regression analysis. Differential gene expression analysis was performed by the NetworkAnalyst platform based on data from the Gene Expression Omnibus (GEO). The expression of CD39 on CD8+ T cells in the CK+ region was higher in cancer tissue than in paracancerous tissue (p = 0.011), and high CD39-expressing CD8+ T cells in the CK+ region (HR, 2.587; p = 0.033) and high CD39-expressing CD8+ T cells in the CK- region (HR, 3.090; p = 0.008) were independent risk factors for prognosis in ESCC patients; the expression of ENTPD1 was upregulated in ESCC tissues compared to normal tissues (adjusted p < 0.001; log2 fold change = 1.99), and its expression was significantly positively correlated with the expression of PDCD1, CTLA4, and HAVCR2. High CD39-expressing CD8+ T cells can be used as a new molecular marker for the diagnosis and prognosis of ESCC, and the restoration of partially exhausted CD8+ T cells by inhibiting CD39 may be a new strategy for treating ESCC.
基金：
This research was funded by the Key R&D Program of Hebei Province, grant number
213777105D, the 2020 Funding Program for the Introduction of Overseas Chinese Scholars, grant
number c20200352, and the Undergraduate Innovational Experimentation Program of Hebei Medical
University, grant number USIP2022094
第一作者机构：[1]Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
通讯作者：
通讯机构：[1]Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.[5]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
推荐引用方式(GB/T 7714)：
Liu Meitong,Zhao Yaning,Xiao Zhuoyun,et al.CD39-Expressing CD8+ T Cells as a New Molecular Marker for Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma[J].CANCERS.2023,15(4):doi:10.3390/cancers15041184.
APA：
Liu Meitong,Zhao Yaning,Xiao Zhuoyun,Zhou Rongmiao,Chen Xiaodong...&Wang Na.(2023).CD39-Expressing CD8+ T Cells as a New Molecular Marker for Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.CANCERS,15,(4)
MLA：
Liu Meitong,et al."CD39-Expressing CD8+ T Cells as a New Molecular Marker for Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma".CANCERS 15..4(2023)
